New Delhi, Mar 4 () National drug pricing regulator NPPA has said medical devices makers and importers are being given the last opportunity to submit data regarding price movement of 19 medical devices notified as drugs by March 15, 2018.
Ten days after he released evidence of profiteering by private hospitals when dengue broke out, National Pharmaceutical Pricing Authority (NPPA) chairman Bhupendra Singh was transferred on Wednesday night. The NPAA investigation found that four private hospitals were forcing patients to buy drugs from in-house pharmacies after increasing price margins by nearly 2,000% in some cases.
The pharmaceutical industry has suggested to the central government that it should increase its reviewing powers on the decisions taken by National Pharmaceutical Pricing Authority (NPPA). The regulator is learnt to have responded with a contrarian view that the government should “abandon its archaic practice of reviewing NPPA orders” and, instead, establish an independent appellate tribunal.
NEW DELHI: Drug price regulator NPPA today said it has decided not to stop any coronary stent manufacturer from withdrawing products from the Indian market. The National Pharmaceutical Pricing Authority (NPPA) said however that the companies will have to follow mandatory requirement of informing it six months in advance as prescribed under Drugs Prices Control Order (DPCO), 2013, while also following the ceiling price.
Some hospitals in the National Capital Region (NCR) prescribed branded medicines that were outside the regulator’s purview and inflated their prices several times in order to boost profit, the National Pharmaceutical Pricing Authority said. Four hospitals in the NCR marked up the retail prices of such medicines as much as 12-fold from the rates at which they were purchased, NPPA said in a report.
National Pharmaceutical Pricing Authority (NPPA) on Tuesday came out with a price analysis of three unnamed private hospitals in the city that showed huge margins on MRPs kept by these hospitals on drugs and consumables, ranging from 2112 per cent to 116 per cent.
Hospitals across the Capital maintained that they have revised and are offering the new, low-priced stents rates as per direction of the National Pharmaceutical Pricing Authority (NPPA) which came in earlier this month. Cardiologists have welcomed the lowered-price list stating that the benefit will be seen immediately.
While the National Pharmaceutical Pricing Authority (NPPA) revised the ceiling price on coronary stents on Monday, its Chairman Bhupendra Singh stated on Friday that that the price control is not the best option to achieve affordability. “If you ask me, I don’t consider that price control is the best option to achieve affordability.
After price caps on cardiac stents and knee implants, a cap is now eagerly awaited on hip implants, which too are highly priced due to excessive profiteering by manufacturers, distributors as well as healthcare providers. “The price control on all implants has been widely discussed.
The National Pharmaceutical Pricing Authority on Monday revised the price of drug eluting stents (DES) downwards by about Rs 2,300 to just under Rs 28,000, while marginally raising the cap on bare metal stents from Rs 7,400 to Rs 7,660. These caps are excluding GST.
The National Pharmaceutical Pricing Authority (NPPA) revised the price cap on coronary stents on Monday wherein the drug eluting stents (DES) and bare metal stents (BMS) would now have the ceiling price of Rs 27, 890 and Rs 7,660.
The government’s move to cap the maximum price of cardiac stents has reduced angioplasty procedure costs in tier 1 and metro corporate chains and standalone private hospitals up to 18%, according to a study commissioned by Advanced Medical Technology Association( AdvaMed), a lobby group of multinational medical device makers.
MUMBAI | NEW DELHI: Five pharmaceutical companies including Cipla, Hetero and Dr Reddy’s Laboratories are under the Indian regulator’s scanner for allegedly overcharging for a new Hepatitis C combination which they launched without waiting for price approval.